about
Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational CohortFour years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.Ageing with HIV: a multidisciplinary review.Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study.Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.Decreasing cardiovascular risk in HIV infection between 2005 and 2011.An unusual case of epigastric and back pain: expanding descending thoracic aneurysm resulting from tertiary syphilis diagnosed with positron emission tomography.Cerebrospinal fluid penetration of tigecycline.Syphilis as a diagnosis of liver abnormalities in HIV.Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study.Fusobacterium nucleatum endocarditis mimicking polymyalgia rheumatica.Erratum to: Ageing with HIV: a multidisciplinary review.Low frequency of skin reactions in a cohort of patients on raltegravir.AmBisome administration for Candida albicans shunt infections.Cardiovascular risk assessment in antiretroviral-naïve HIV patients.Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy.Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study.Entecavir to treat severe acute hepatitis B.Efavirenz and bone health.Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma.Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy.[Loa loa filariasis in Italy: review of the literature with a clinical report].Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study.Chronological and biological age in HIV infection.Adherence to antiretroviral therapy in HIV patients with psychiatric comorbidity.A giant pancreatic pseudocyst in a patient with HIV infection.Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective studyWaist circumference and body mass index in HIV infectionNegative Influence of HIV Infection on Day-Night Blood Pressure VariabilityCholesterol levels in HIV–HCV infected patients treated with lopinavir/r: Results from the SCOLTA project
P50
Q28552719-1AA4871C-A44C-4EDB-813A-20175190C83BQ30710478-CF4E9C0A-3B4C-47BF-A24E-63E904706142Q34341541-F2496A6C-34CE-43F3-86C3-9EF75516EC76Q36033710-453E6483-91BD-4AA3-AB7D-99ACF6E42CD2Q38490362-ACD917FA-8D97-4856-97EC-99C669980064Q38779256-533CAE36-3CCA-45B9-AFD7-5199AF5B7CFEQ39861096-CE833A30-C484-4B7C-8267-849F20AAC97EQ40439011-5E75D33C-2AE2-40B4-9C42-58AD03B62F7FQ40467061-2CB2D0B1-C4E8-406F-AA3F-AB6C3A5DC9A4Q41496212-72116E61-9109-4374-A6DC-747F5EB7EB5EQ42234707-D17CC935-31AE-42F0-9BEA-1A102D12AA02Q42240002-105790C1-DEAA-4E4B-9D03-36E0B3471245Q42244001-2A457462-5B3A-42FB-96F8-185259B7CB93Q42263169-CDC30627-074D-4EB3-8821-89D091EE6202Q42273711-D3D58839-14D6-46B2-B7DC-A8F9E33E5258Q42273839-CECAB326-7C11-404F-97CF-5B0AAEF57CB4Q43105609-757543D7-2FBB-4D4B-87C9-D5F6FFCBF8CBQ43279417-93243E75-113F-4CC0-960D-C20FA6785117Q43521513-5D2D0E10-985B-468A-9D1F-1C4E6EB7C6EEQ44532546-1545B327-071C-4C25-82D2-2518975702C2Q44636903-9C596FDF-9017-4CEE-B81D-2B31A19DE454Q44681586-16FF2816-2283-4593-86FA-68C298497144Q45089033-8EE1C220-3DD0-407D-8D8C-DF383044C202Q45369642-80730677-C142-43EB-BFBF-0C23C3B24C5BQ45959477-C6772324-7E80-4F34-8D2E-665EDD5092D6Q46006592-4CE8D428-96A4-4F38-A8D3-224BFC0BB2E6Q46340494-B76EE22E-5533-42A1-94E8-E9BC768CF1EAQ46627265-E161ECD1-A7E3-4F1D-80FA-FF0D9FF8DDA7Q46843503-37136085-3923-4DF0-8863-BFD8B461CA49Q50593815-99E680D0-26B0-413A-B7B8-A476C466880EQ51283410-CE64F541-BB78-40F8-B4CD-FDD21E40BAAEQ51662146-B6DA179D-4F3D-48EC-A17F-0DF4906BA256Q51939325-B7F8851E-C112-4442-B9F1-6A6DE4E3D52CQ53163264-FA9FEC49-C4FC-4665-9191-678F26882113Q53702107-058F6755-D018-4B25-AC6D-51FF0D3E3850Q54942910-D56F8A08-42D7-4A27-BA89-38D0D3C0E3D3Q58388940-E6D4F3ED-BB72-4286-99D0-44FA1FB4ACA0Q58812108-C6162DE7-65B4-4409-A197-A4D1C1802381Q58812114-6C42CFAB-17AB-436D-AA4C-5E8543BA961CQ58812142-DFF7E18F-6BC3-48BC-B74A-25A7082411D6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Vittorio Luigi De Socio
@ast
Giuseppe Vittorio Luigi De Socio
@en
Giuseppe Vittorio Luigi De Socio
@es
Giuseppe Vittorio Luigi De Socio
@nl
Giuseppe Vittorio Luigi De Socio
@sl
type
label
Giuseppe Vittorio Luigi De Socio
@ast
Giuseppe Vittorio Luigi De Socio
@en
Giuseppe Vittorio Luigi De Socio
@es
Giuseppe Vittorio Luigi De Socio
@nl
Giuseppe Vittorio Luigi De Socio
@sl
prefLabel
Giuseppe Vittorio Luigi De Socio
@ast
Giuseppe Vittorio Luigi De Socio
@en
Giuseppe Vittorio Luigi De Socio
@es
Giuseppe Vittorio Luigi De Socio
@nl
Giuseppe Vittorio Luigi De Socio
@sl
P106
P1153
6603866364
P21
P31
P496
0000-0001-8774-4843